

David Price

Research Articles

1. McKeever T, **Price D**, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. *N Engl J Med* 2018; 378(10): 902-910. [PubMed] [Full Text]
2. **Price D**, et al. Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 695-702. [PubMed] [Full Text]
3. Miravittles M, **Price DB**, et al. Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. *Respir Med* 2018; 136: 8-14. [PubMed] [Full Text]
4. **Price DB**, et al. Real-life effectiveness and safety of Salbutamol Steri-neb™ vs. Ventolin Nebules® in preventing exacerbations in patients with COPD: historical cohort study. *PLoS One* 2018; 13(1): e0191404. [PubMed] [Full Text]
5. Kerckhof M, **Price DB**, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. *Thorax* 2018; 73: 116-124. [PubMed] [Full Text]
6. Bosnic-Anticevich S, **Price DB**, et al. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. *J Asthma* 2018; 55(1): 79-88. [PubMed] [Full Text]
7. Bruton A, **Price D**, et al. Physiotherapy breathing retraining for asthma: a randomised controlled trial. *Lancet Respir Med* 2017. [PubMed] [Full Text]
8. Colice G, **Price D**, et al. The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship. *Pragmat Obs Res* 2017; 8: 231-240. [PubMed] [Full Text]
9. Tan R, **Price D**, et al. Identifying the hidden burden of Allergic Rhinitis (AR) in community pharmacy: a global phenomenon. *Asthma Res Pract* 2017; 3: 8. [PubMed] [Full Text]
10. van der Molen T, Fletcher M, and **Price D**. Identifying patient attitudinal clusters associated with asthma control: the European REALISE survey. *J Allergy Clin Immunol Pract* 2017. [PubMed] [Full Text]
11. Smid DE, **Price D**, et al. Redefining cut-points for high symptom burden of the Global Initiative for Chronic Obstructive Lung Disease classification in 18,577 patients with chronic obstructive pulmonary disease. *J Am Med Dir Assoc* 2017; 8(12): 1097.e11–1097.e24. [PubMed] [Full Text]
12. Chapman S, **Price D**, et al. Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. *NPJ Prim Care Respir Med* 2017; 27(1): 61. [PubMed] [Full Text]
13. **Price DB**, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. *Lancet Respir Med* 2017. [PubMed] [Full Text]
14. Bosnic-Anticevich S, **Price D**, et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed dose combination therapy in Australia. *J Asthma* 2017; 8: 1-11. [PubMed] [Full Text]
15. Carney AS, **Price DB**, et al. Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study. *Pragmat Obs Res* 2017; 8: 157-165. [PubMed] [Full Text]
16. Jones R, **Price D**, et al. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 2445-2454. [PubMed] [Full Text]
17. Nibber A, **Price D**, et al. Validating the concept of COPD control: a real-world cohort study from the United Kingdom. *COPD* 2017; 14(5): 504-512. [PubMed] [Full Text]
18. Wan Yau Ming S, **Price DB**, et al. Initiating or changing to a fixed-dose combination of fluticasone propionate/formoterol over fluticasone propionate/salmeterol: a real-life effectiveness and cost impact evaluation. *Respir Med* 2017; 129: 199-206. [PubMed] [Full Text]
19. Barry LE, **Price D**, et al. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. *Respir Res* 2017; 18(129). [PubMed] [Full Text]
20. Sonnappa S, **Price DB**, et al. Risk of pneumonia in obstructive lung disease: a real-life study comparing extra-fine and fine-particle inhaled corticosteroids. *PLoS One* 2017; 12(6): e0178112. [PubMed] [Full Text]
21. **Price DB**, et al. Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database. *Pragmat Obs Res* 2017; 8: 69-83. [PubMed] [Full Text]
22. Smith P, **Price D**, et al. Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. *J Asthma Allergy* 2017; 10: 153-61. [PubMed] [Full Text]
23. Scadding G, **Price D**, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. *BMJ Open* 2017; 7: e014777. [PubMed] [Full Text]
24. Voorham J, **Price DB**, et al. Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. *Pragmat Obs Res* 2017; 8: 31-41. [PubMed] [Full Text]
25. Usmani OS, **Price DB**, et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. *J Allergy Clin Immunol Pract* 2017; 5(5): 1378-1387.e5. [PubMed] [Full Text]
26. Dollerup J, **Price DB**, et al. Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. *Clin Epidemiol* 2017; 9: 231-43. [PubMed] [Full Text]
27. Thomas V, **Price DB**, et al. Ipratropium/Salbutamol comparator versus originator for chronic obstructive pulmonary disease exacerbations: US observational cohort study using the Clininformatics™ health claims database. *Pulm Ther* 2017; 3(1): 187-205. [Full Text]

28. Souverein PC, **Price D** et al.; on behalf of the Respiratory Effectiveness Group's Adherence Working Group. Inhaled corticosteroid adherence patterns in a longitudinal asthma cohort. *J Allergy Clin Immunol Pract* 2017; 5(2): 448-456.e2. [PubMed] [Full Text]
29. Postma DS, **Price DB**, et al. Cohort analysis of exacerbation rates in adolescent and adult patients initiating inhaled corticosteroids for asthma: different dose-response profile by particle size. *Pulm Ther* 2017; 3(1): 113-124. [Full Text]
30. Burden A, **Price DB**, et al. An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma. *Pragmat Obs Res* 2017; 8: 15-30. [PubMed] [Full Text]
31. Ryan D, **Price D**, et al.; on behalf of the Respiratory Effectiveness Group. Use of electronic medical records and biomarkers to manage risk and resource efficiencies. *Eur Clin Respir J* 2017; 4(1): 1293386. [PubMed] [Full Text]
32. **Price DB**, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. *J Allergy Clin Immunol Pract* 2017; 5(4): 1071-81.e9. [PubMed] [Full Text]
33. Murray CS, **Price DB**, et al. Comparative effectiveness of step-up therapies in children with asthma prescribed inhaled corticosteroids: a historical cohort study. *J Allergy Clin Immunol Pract* 2017; 5(4): 1082-1090.e7. [PubMed] [Full Text]
34. Pavord ID, **Price D**, et al. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β 2- agonists in the United Kingdom: a cross-sectional analysis. *NPJ Prim Care Respir Med* 2017; 27: 17. [PubMed] [Full Text]
35. Rodrigo GJ, **Price D**, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 907-22. [PubMed] [Full Text]
36. Turner S, **Price DB**, et al.; Respiratory Effectiveness Group. Long-acting β -agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. *J Allergy Clin Immunol Pract* 2017; 5(1): 99-106.e3. [PubMed] [Full Text]
37. Guilbert TW, **Price DB**, et al.; in collaboration with the Respiratory Effectiveness Group. Real-life outcomes for patients with asthma prescribed spacers for use with either extrafine- or fine-particle inhaled corticosteroids. *J Allergy Clin Immunol Pract* 2017; 5(4): 1040-1049.e4. [PubMed] [Full Text]
38. J Bousquet, **Price D**, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries. The MASK-rhinitis study. *Allergy* 2017. [PubMed] [Full Text]
39. Chisholm A, **Price D**, et al. Personalising care of adults with asthma from Asia: a modified e-Dephi consensus study to inform management tailored to attitude and control profiles. *NPJ Prim Care Respir Med* 2017; 27: 16089. [PubMed] [Full Text]
40. David-Wang A, **Price D**, et al.; for the REcognise Asthma and Link to Symptoms and Experience (REALISE) Asia Working Group. Development and validation of an attitudinal-profiling tool for patients with asthma. *Allergy Asthma Immunol Res* 2017; 9(1): 43-51. [PubMed] [Full Text]
41. Bosnic-Anticevich S, **Price DB**, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 59-71. [PubMed] [Full Text]
42. Blakey JD, **Price DB**, et al. Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group initiative. *J Allergy Clin Immunol* 2016; 5(4): 1015-1024.e8. [PubMed] [Full Text]
43. Ställberg B, **Price D**, et al. The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG. *NPJ Prim Care Respir Med* 2016; 26: 16069. [PubMed] [Full Text]
44. **Price D**, et al. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. *NPJ Prim Care Respir Med* 2016; 26: 16061. [PubMed] [Full Text]
45. Belhassen M, **Price D**, et al. Inappropriate asthma therapy — a tale of two countries: a parallel population-based cohort study. *NPJ Prim Care Respir Med* 2016; 26: 16076. [PubMed] [Full Text]
46. Skeggs A, **Price D**, et al. FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. *Trials* 2016; 17: 499. [PubMed] [Full Text]
47. Postma DS, **Price DB**, et al. Asthma-related outcomes in patients initiating extrafine ciclesonide or fine-particle inhaled corticosteroids. *Allergy Asthma Immunol Res* 2017; 9(2): 116-25. [PubMed] [Full Text]
48. Dekhuijzen PNR, **Price DB**, et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. *Respir Med* 2016; 120: 54-63. [PubMed] [Full Text]
49. **Price DB**, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. *PLoS One* 2016; 11(9): e0162903. [PubMed] [Full Text]
50. Halpin DMG, **Price DB**, et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. *Respir Res* 2016; 17(1): 120. [PubMed] [Full Text]
51. **Price DB**, et al. Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease. *J Asthma Allergy* 2016; 9: 145-54. [PubMed] [Full Text]
52. Klimek L, **Price D**, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: a pan-European study. *Allergy Asthma Proc* 2016; 37(5): 376-86. [PubMed] [Full Text]
53. Maleki-Yazdi MR, **Price D**, et al. Cost effectiveness of the long-acting β 2-adrenergic agonist (LABA)/long-acting muscarinic antagonist dual bronchodilator indacaterol/glycopyrronium versus the LABA/inhaled corticosteroid combination salmeterol/fluticasone in patients with chronic obstructive pulmonary disease: analyses conducted for Canada, France, Italy, and Portugal. *Appl Health Econ Health Policy* 2016; 14(5): 579-94. [PubMed] [Full Text]
54. Lipworth B, **Price DB**, et al. Underuse of β -blockers in heart failure and chronic obstructive pulmonary disease. *Heart* 2016; 102(23): 1909-14. [PubMed] [Full Text]
55. **Price DB**, et al. UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study. *NPJ Prim Care Respir Med* 2016; 26:16033. [PubMed] [Full Text]
56. Happich M, **Price D**, et al. Excess costs associated with possible misdiagnosis of Alzheimer's disease among patients with vascular dementia in a UK CPRD population. *J Alzheimers Dis* 2016; 53(1): 171-83. [PubMed] [Full Text]

57. **Price DB**, et al. Add-on LABA in a separate inhaler as asthma step-up therapy versus increased dose of ICS or ICS/LABA combination inhaler. *ERJ Open Res* 2016; 2(2). [PubMed] [Full Text]
58. van der Molen T, **Price DB**, et al. Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. *BMC Pulm Med* 2016; 16(1): 80. [PubMed] [Full Text]
59. Braido F, **Price D**, et al.; LIAISON Study Group. Determinants and impact of suboptimal asthma control in Europe: The International cross-sectional and longitudinal assessment of asthma control (LIAISON) study. *Respir Res* 2016; 17(1): 51. [PubMed] [Full Text]
60. Sastre J, **Price D**, et al. Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. *World Allergy Organ J* 2016; 9: 13. [PubMed] [Full Text]
61. Upton J, **Price D**, et al. Asthma-specific health related quality of life of people in Great Britain: A national survey. *J Asthma* 2016; 26:1-8. [PubMed] [Full Text]
62. **Price D**, et al. Asthma in Asia: Physician perspectives on control, inhaler use and patient communications. *J Asthma* 2016; 53(7): 761-9. [PubMed] [Full Text]
63. Lee H, **Price D**, et al. Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database. *Int J Chron Obstruct Pulmon Dis* 2016; 11(1): 775–83. [PubMed] [Full Text]
64. Lisspers K, **Price D**, et al. Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. *NPJ Prim Care Respir Med* 2016; 26: 16016. [PubMed] [Full Text]
65. Jones RC, **Price D**, et al.; UNLOCK Group of the IPCRG. Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets. *NPJ Prim Care Respir Med* 2016; 26: 16010. [PubMed] [Full Text]
66. Sweeney J, **Price D**, et al.; on behalf of the British Thoracic Society Difficult Asthma Network. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. *Thorax* 2016; 71(4): 339-46. [PubMed] [Full Text]
67. Fletcher M, **Price D**, et al. Patient reported burden of asthma on resource use and productivity across 11 countries in Europe. *Adv Ther* 2015; 32(4): 370-80. [PubMed] [Full Text]
68. Roche N, **Price DB**, et al. Cost-effectiveness of asthma step-up therapy as an increased dose of extrafine-particle inhaled corticosteroid or add-on long-acting beta₂-agonist. *Pulm Ther* 2016; 2: 73-89. [Full Text]
69. Miravittles M, **Price D**, et al. The relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an observational study (ASSESS). *COPD* 2016; 13(5): 561-8. [PubMed] [Full Text]
70. Gruffydd-Jones K, **Price D**, et al. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observational. *NPJ Prim Care Respir Med* 2016; 26: 16002. [PubMed] [Full Text]
71. Westerik JA, **Price DB**, et al. Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. *J Asthma* 2016; 53(3): 321-9. [PubMed] [Full Text]
72. Chrystyn H, **Price DB**, et al. Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study. *BMC Pulm Med* 2016; 16(1):12. [PubMed] [Full Text]
73. **Price D**, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. *J Asthma Allergy* 2016; 9: 1-12. [PubMed] [Full Text]
74. Klimek L, **Price D**, et al. Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) for allergic rhinitis. *Expert Opin Drug Saf* 2016; 15(1): 117-29. [PubMed] [Full Text]
75. Costa-Scharplatz M, **Price D**, et al. Cost-effectiveness of glycopyrronium bromide compared with tiotropium in patients with chronic obstructive pulmonary disease in Sweden. *Appl Health Econ Health Policy* 2015; 13(6): 637-45. [PubMed] [Full Text]
76. **Price D**, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. *Clin Transl Allergy* 2015; 5: 39. [PubMed] [Full Text]
77. Nwokoro C, **Price D**, et al. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial. *Efficacy and Mechanism Evaluation* 2015; 26. [PubMed] [Full Text]
78. Kerkhof M, **Price DB**, et al.; Respiratory Effectiveness Group. Predicting frequent COPD exacerbations using primary care data. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 2439-50. [PubMed] [Full Text]
79. **Price DB**, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. *Lancet Respir Med* 2015; 3(11): 849–58. [PubMed] [Full Text]
80. Hellings PW, **Price D**, et al. A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. *Clin Transl Allergy* 2015; 5: 36. [PubMed] [Full Text]
81. **Price D**, et al. Time for a new language for asthma control: results from REALISE Asia. *J Asthma Allergy* 2015; 8: 93-103. [PubMed] [Full Text]
82. Brusselle G, **Price D**, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 2207-17. [PubMed] [Full Text]
83. Nathan RA, **Price D**, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific region, Latin America, Europe, Canada, and the United States. *J Allergy Clin Immunol Pract* 2015; 3(5): 734-42.e5 [PubMed] [Full Text]
84. van Aalderen WM, **Price D**, et al. Small-particle inhaled corticosteroid as first-line or step-up controller therapy in childhood asthma. *J Allergy Clin Immunol Pract* 2015; 3(5): 721-31.e16. [PubMed] [Full Text]
85. **Price D**, et al. Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians. *World Allergy Organ J* 2015; 8(1): 26. [PubMed] [Full Text]
86. Turner SW, **Price D**, et al. Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study. *NPJ Prim Care Respir Med* 2015; 25: 15041. [PubMed] [Full Text]

87. Devereux G, **Price D**, et al. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. *Trials* 2015; 16: 267. [PubMed] [Full Text]
88. Israel E, **Price DB**, et al. Increased dose of inhaled corticosteroid versus add-on long-acting β -agonist for step-up therapy in asthma. *Ann Am Thorac Soc* 2015; 12(6): 798-806. [PubMed] [Full Text]
89. Cazzola M, **Price D**, et al. Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. *Pulm Pharmacol Ther* 2015; 31: 68-78. [PubMed] [Full Text]
90. Miravittles M, **Price D**, et al. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 549-64. [PubMed] [Full Text]
91. Papi A, **Price D**, et al. Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis. *Respir Med* 2015; 109(2): 208-17. [PubMed] [Full Text]
92. Klimek L, **Price D**, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. *Allergy Asthma Proc* 2015; 36(1): 40-7. [PubMed] [Full Text]
93. **Price D**, et al. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. *J Asthma Allergy* 2015; 8: 1-13. [PubMed] [Full Text]
94. Miravittles M, **Price D**, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. *Respir Res* 2014; 15: 122. [PubMed] [Full Text]
95. Park HS, **Price D**, et al. Physician-prescribed asthma treatment regimen does not differ between smoking and non-smoking patients with asthma in Seoul and Gyunggi province of Korea. *Allergy Asthma Immunol Res* 2014; 6: 30-6. [PubMed] [Full Text]
96. **Price D**, et al. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. *Respir Med* 2014; 108(12): 1786-93. [PubMed] [Full Text]
97. Toumas-Shehata M, **Price D**, et al. Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel-group, repeated-measures study. *NPJ Prim Care Respir Med* 2014; 13(24): 14071. [PubMed] [Full Text]
98. Postma DS, **Price D**, et al. Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 1163-86. [PubMed] [Full Text]
99. Nwokoro C, **Price D**, et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial. *Lancet Respir Med* 2014; 2(10): 796-803. [PubMed] [Full Text]
100. Martin RJ, **Price D**, et al. Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. *NPJ Prim Care Respir Med* 2014; 24: 14081. [PubMed] [Full Text]
101. **Price D**, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 889-904. [PubMed] [Full Text]
102. Ching SM, **Price D**, et al. Detection of airflow limitation using a handheld spirometer in a primary care setting. *Respirology* 2014; 19(5): 689-93. [PubMed] [Full Text]
103. Brockwell C, **Price D**, et al. Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 715-21. [PubMed] [Full Text]
104. **Price D**, et al. Asthma control and management in 8,000 European patients: the REcognise Asthma and Link to Symptoms and Experience (REALISE) survey. *NPJ Prim Care Respir Med* 2014; 12(24): 14009. [PubMed] [Full Text]
105. **Price D**, et al. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 551-61. [PubMed] [Full Text]
106. **Price D**, et al. Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. *J Asthma Allergy* 2014; 10(7): 31-51. [PubMed] [Full Text]
107. Jones R, **Price D**, et al.; Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. *Lancet Respir Med* 2014; 2(4): 267-76. [PubMed] [Full Text]
108. Berger W, **Price D**, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. *J Allergy Clinical Immunol Pract* 2014; 2(2): 179-85. [PubMed] [Full Text]
109. **Price D**, et al. Types, frequency and impact of asthma triggers on patients' lives: a quantitative study in 5 European countries. *J Asthma* 2014; 51(2): 127-35. [PubMed] [Full Text]
110. **Price D**, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. *J Investig Allergol Clin Immunol* 2013; 23(7): 495-503. [PubMed] [Full Text]
111. **Price D**, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. *Prim Care Respir J* 2013; 22(4): 439-48. [PubMed] [Full Text]
112. **Price D**, et al. Impact of night-time symptoms in COPD: a real-world study in five European countries. *Int J Chron Obstruct Pulmon Dis* 2013; 8: 595-603. [PubMed] [Full Text]
113. **Price D**, et al. Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. *Clin Transl Allergy* 2013; 3(1): 37. [PubMed] [Full Text]
114. **Price D**, et al. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. *Respir Med* 2013; 107(7): 987-1000. [PubMed] [Full Text]
115. Colice G, **Price D**, et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. *J Allergy Clin Immunol* 2013; 132(1): 45-54. [PubMed] [Full Text]
116. **Price D**, et al. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use. *Appl Health Econ Health Policy* 2013; 11(3): 259-74. [PubMed] [Full Text]
117. **Price D**, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. *Prim Care Respir J* 2013; 22(2): 161-8. [PubMed] [Full Text]

118. Bruton A, **Price D**, et al. The BREATHE study: Breathing REtraining for Asthma - trial of home exercises. A protocol summary of a randomised controlled trial. *Prim Care Respir J* 2013; 22: PS1-7. [PubMed] [Full Text]
119. Meltzer E, **Price D**, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. *Int Arch Allergy Immunol* 2013; 161(4): 369-77. [PubMed] [Full Text]
120. Braido F, **Price D**, et al. International cross-sectional and longitudinal assessment on asthma control in European adult patients—the LIAISON study protocol. *BMC Pulm Med* 2013; 13: 18. [PubMed] [Full Text]
121. **Price D**, et al. Effect of montelukast for treatment of asthma in cigarette smokers. *J Allergy Clin Immunol* 2013; 131(3): 763-71. [PubMed] [Full Text]
122. Lenney W, **Price D**, et al. MASCOT Study Group. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. *Health Technol Assess* 2013; 17(4): 1-218. [PubMed] [Full Text]
123. **Price D**, et al. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. *J Allergy Ther* 2013; 4(1): 126. [Full Text]
124. Smith JR, **Price DB**, et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. *Thorax* 2012; 67(12): 1052-60. [PubMed] [Full Text]
125. Carr W, **Price D**, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. *Allergy Asthma Proc* 2012; 33(6): 450-8. [PubMed] [Full Text]
126. Pinnock H, **Price DB**, et al. Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study. *Prim Care Respir J* 2010; 21(3): 288-94. [PubMed] [Full Text]
127. Malhotra S, **Price DB**, et al. The challenge of recruiting in primary care for a trial of telemonitoring in asthma: an observational study. *Pragmat Obs Res* 2012; 3(1): 51-5. [PubMed] [Full Text]
128. Meltzer EO, **Price D**, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. *Allergy Asthma Proc* 2012; 33(4): 324-32. [PubMed] [Full Text]
129. **Price D**, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. *Allergy Asthma Immunol Res* 2012; 4(4): 184-91. [PubMed] [Full Text]
130. Carr W, **Price D**, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *J Allergy Clin Immunol* 2012; 129(5): 1282-9. [PubMed] [Full Text]
131. Ryan D, **Price D**, et al. Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. *BMJ* 2012; 344: e1756. [PubMed] [Full Text]
132. Bousquet J, **Price D**, et al.; Global Allergy and Asthma European Network (GA²LEN). Inhaled corticosteroid/long-acting β_2 -agonist combination therapy for asthma: attitudes of specialists in Europe. *Int Arch Allergy Immunol* 2012; 157(3): 303-10. [PubMed] [Full Text]
133. Thomas M, **Price D**, et al. Physicians' attitudes towards combination therapy with inhaled corticosteroids and long-acting β_2 -agonists: an observational study in UK specialist care. *Pragmat Obs Res* 2011; 2: 25-31. [PubMed] [Full Text]
134. **Price D**, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. *Respir Med* 2011; 105(11): 1635-47. [PubMed] [Full Text]
135. Barnes N, **Price D**, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. *Clin Exp Allergy* 2011; 41(11): 1521-32. [PubMed] [Full Text]
136. **Price D**, et al. Device type and real-world effectiveness of asthma combination therapy: An observational study. *Respir Med* 2011; 105(10): 1457-66. [PubMed] [Full Text]
137. Kielmann T, **Price D**, et al. From awareness to involvement? A qualitative study of respiratory patients' awareness of health service change. *Health Expect* 2011; 14(3): 321-33. [PubMed] [Full Text]
138. **Price D**, et al. A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). *Health Technol Assess* 2011; 15(21): 131-2. [PubMed] [Full Text]
139. **Price D**, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. *N Engl J Med* 2011; 364(18): 1695-707. [PubMed] [Full Text]
140. **Price D**, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. *J Asthma Allergy* 2011; 4: 37-47. [PubMed] [Full Text]
141. Zhang Q, **Price D**, et al. Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK. *Prim Care Respir J* 2011; 20(1): 408. [PubMed] [Full Text]
142. Chavannes N, **Price D**, et al. UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance Knowledge. *Prim Care Respir J* 2010; 19(4): 408. [PubMed] [Full Text]
143. **Price D**, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. *J Allergy Clin Immunol* 2010; 126(3): 511-8.e10. [PubMed] [Full Text]
144. **Price D**, et al. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. *Prim Care Respir J* 2010; 19(3): 266-73. [PubMed] [Full Text]
145. Kemp L, **Price D**, et al. Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study. *Clinicoecon Outcome Res* 2010; 2: 75-85. [PubMed] [Full Text]
146. Wilson EC, **Price D**, et al. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. *Pharmacoeconomics* 2010; 28(7): 597-608. [PubMed] [Full Text]
147. Wilson EC, **Price D**, et al. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. *Pharmacoeconomics* 2010; 28(7): 585-95. [PubMed] [Full Text]
148. Faulkner J, **Price D**, et al. The feasibility of recruiting patients with early COPD to a pilot trial assessing the effects of a physical activity intervention. *Prim Care Respir J* 2010; 19(2): 124-30. [PubMed] [Full Text]

149. Kielmann T, **Price D**, et al. From support to boundary: A qualitative study of the border between self-care and professional care. *Patient Educ Couns* 2010; 79(1): 55-61. [PubMed] [Full Text]
150. Doyle S, **Price D**, et al. What happens to patients who have their asthma device switched without their consent?. *Prim Care Respir J* 2010; 19(2): 131-9. [PubMed] [Full Text]
151. **Price D**, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. *BMC Pulm Med* 2010; 10: 1. [PubMed] [Full Text]
152. Jones RC, **Price D**, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. *Am J Respir Crit Care Med* 2009; 180(12): 1189-95. [PubMed] [Full Text]
153. Clatworthy J, **Price D**, et al. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. *Prim Care Respir J* 2009; 18(4): 300-5. [PubMed] [Full Text]
154. Ryan D, **Price D**, et al. The CYMPLA trial. Mobile phone-based structured intervention to achieve asthma control in patients with uncontrolled persistent asthma: a pragmatic randomised controlled trial. *Prim Care Respir J* 2009; 18(4): 343-5. [PubMed] [Full Text]
155. Taegtmeyer AB, **Price DB**, et al. Predictors of asthma control in everyday clinical practice in Switzerland. *Curr Med Res Opin* 2009; 25(10): 2549-55. [PubMed] [Full Text]
156. Wilson E, **Price D**, et al. Befriending carers of people with dementia: a cost utility analysis. *Int J Geriatr Psychiatry* 2009; 24(6): 610-23. [PubMed] [Full Text]
157. Winchester CC, **Price D**, et al. Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care. *Chest* 2009; 135(5): 1163-72. [PubMed] [Full Text]
158. Thomas M, **Price D**, et al. The Asthma Control Test™ (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. *Prim Care Resp J* 2009; 18(1): 41-9. [PubMed] [Full Text]
159. **Price D**, et al. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. *Allergy* 2009; 64(3): 431-8. [PubMed] [Full Text]
160. Van Cauwenberge P, **Price D**, et al. The current burden of allergic rhinitis amongst primary care practitioners and its impact on patient management. *Prim Care Respir J* 2009; 18(1): 27-33. [PubMed] [Full Text]
161. Thomas M, **Price D**, et al. Breathing exercises for asthma: a randomised controlled trial. *Thorax* 2009; 64(1): 55-61. [PubMed] [Full Text]
162. Thomas M, **Price D**, et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. *BMC Pul Med* 2009; 9: 1. [PubMed] [Full Text]
163. Thomas M, **Price D**, et al. High-dose inhaled corticosteroids versus add-on long-acting beta-agonists in asthma: an observational study. *J Allergy Clin Immunol* 2009; 123(1):116-21. e10. [PubMed] [Full Text]
164. Turner SW, **Price D**, et al. Prescribing trends in asthma: a longitudinal observational study. *Arch Dis Child* 2009; 94(1): 16-22. [PubMed] [Full Text]
165. Green RJ, **Price D**, et al. Perceptions, impact and management of asthma in South Africa: a patient questionnaire study. *Prim Care Respir J* 2008; 17(4): 212-6. [PubMed] [Full Text]
166. Griffin J, **Price D**, et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. *Prim Care Respir J* 2008; 17(2): 104-10. [PubMed] [Full Text]
167. Charlesworth G, **Price D**, et al. Befriending carers of people with dementia: randomised controlled trial. *BMJ* 2008; 336(7656): 1295-7. [PubMed] [Full Text]
168. Harnest U, **Price D**, et al. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial. *J Asthma* 2008; 45(3): 215-20. [PubMed] [Full Text]
169. Cleland JA, **Price D**, et al. An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans. *Prim Care Respir J* 2007; 16(5): 311-8. [PubMed] [Full Text]
170. Green RJ, **Price D**, et al. Concerns of patients with allergic rhinitis: the Allergic Rhinitis Care Programme in South Africa. *Prim Care Respir J* 2007; 16(5): 299-303. [PubMed] [Full Text]
171. **Price D**, et al. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. *Allergy* 2007; 62(10): 1189-98. [PubMed] [Full Text]
172. **Price DB**, et al. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. *Respir Res* 2007; 8: 46. [PubMed] [Full Text]
173. Freeman D, **Price D**, et al. Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. *Respir Res* 2007; 8: 45. [PubMed] [Full Text]
174. Van Aalderen WM, **Price D**, et al. Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. *Respir Med* 2007; 101(7): 1585-93. [PubMed] [Full Text]
175. Iversen L, **Price D**, et al. Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability. *Prim Care Respir J* 2007; 16(3): 162-8. [PubMed] [Full Text]
176. Pinnock H, **Price D**, et al. Understanding the potential role of mobile phone based monitoring on asthma self-management: qualitative study. *Clin Exp Allergy* 2007; 37(5): 794-802. [PubMed] [Full Text]
177. Doull I, **Price D**, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. *Curr Med Res Opin* 2007; 23(5): 1147-59. [PubMed] [Full Text]
178. Foster J, **Price D**, et al. Practice development plans to improve the primary care management of acute asthma: randomised controlled trial. *BMC Fam Prac* 2007; 8: 23. [PubMed] [Full Text]
179. Haughney J, **Price D**, et al. The use of a modification of the Patient Enablement Instrument in asthma. *Prim Care Respir J* 2007; 16(2): 89-92. [PubMed] [Full Text]
180. Tinkelman D, **Price D**, et al. COPD screening efforts in primary care: what is the yield?. *Prim Care Respir J* 2007; 16(1): 41-8. [PubMed] [Full Text]

181. Lloyd A, **Price D**, et al. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. *Prim Care Respir J* 2007; 16(1): 22-7. [PubMed] [Full Text]
182. Moffat M, **Price D**, et al. Poor communication may impair optimal asthma care: a qualitative study. *Fam Pract* 2007; 24(1): 65-70. [PubMed] [Full Text]
183. Robertson CF, **Price D**, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. *Am J Respir Crit Care Med* 2007; 175(4): 323-9. [PubMed] [Full Text]
184. Sheikh A, **Price D**, et al. Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial. *Clin Exp Allergy* 2007; 37(1): 90-9. [PubMed] [Full Text]
185. Zhang Q, **Price D**, et al. Treatment and outcomes in patients with asthma and allergic rhinitis in the United Kingdom. *Inter Arch of Allergy and Imm* 2007; 142(4): 318-28. [PubMed] [Full Text]
186. Pearson M, **Price D**, et al. Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997-2001. *Inter J Chron Obstruct Pulmon Dis* 2006; 1(4): 435-43. [PubMed]
187. Thomas M, **Price D**, et al. High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing. *Br J Gen Pract* 2006; 56(531): 788-90. [PubMed] [Full Text]
188. Pinnock H, **Price D**, et al. Professional and patient attitudes to using mobile phone technology to monitor asthma: questionnaire survey. *Prim Care Respir J* 2006; 15(4): 237-45. [PubMed] [Full Text]
189. **Price DB**, et al. Scoring system and clinical application of COPD diagnostic questionnaires. *Chest* 2006; 129(6): 1531-9. [PubMed] [Full Text]
190. Cleland JA, **Price DB**, et al. A pragmatic, three-arm randomised controlled trial of spiritual healing for asthma in primary care. *Br J Gen Pract* 2006; 56(527): 444-9. [PubMed] [Full Text]
191. **Price DB**, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. *Allergy* 2006; 61(6): 737-42. [PubMed] [Full Text]
192. Thomas M, **Price D**, et al. High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study. *Prim Care Respir J* 2006; 15(3): 166-72. [PubMed] [Full Text]
193. Moffat M, **Price D**, et al. Sub-optimal patient and physician communication in primary care consultations: its relation to severe and difficult asthma. *Prim Care Respir J* 2006; 15(3): 159-65. [PubMed] [Full Text]
194. Moffat MA, **Price D**, et al. Can a GP be a generalist and a specialist? Stakeholders views on a respiratory General Practitioner with a special interest service in the UK. *BMC Health Service Res* 2006; 6: 62. [PubMed] [Full Text]
195. Adams R, **Price D**, et al. Exacerbations of chronic obstructive pulmonary disease: A patients' perspective. *Prim Care Respir J* 2006; 15(2): 102-9. [PubMed] [Full Text]
196. Tinkelman DG, **Price DB**, et al. Symptom-based questionnaire for differentiating COPD and asthma. *Respiration* 2006; 73(3): 296-305. [PubMed] [Full Text]
197. **Price DB**, et al. Symptom-based questionnaire for identifying COPD in smokers. *Respiration* 2006; 73(3): 285-95. [PubMed] [Full Text]
198. Tinkelman D, **Price D**, et al. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. *J Asthma* 2006; 43(1): 75-80. [PubMed] [Full Text]
199. Sinclair H, **Price D**, et al. Community pharmacy provision of allergic rhinitis treatments: a longitudinal study of patient reported outcome. *Int J Pharm Pract* 2005; 13(4): 249-56. [Full Text]
200. Vogelmeier C, **Price D**, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. *Eur Respir J* 2005; 26(5): 819-28. [PubMed] [Full Text]
201. Iversen L, **Price DB**, et al. Is living in a rural area good for your respiratory health? Results from a cross-sectional study in Scotland. *Chest* 2005; 128(4): 2059-67. [PubMed] [Full Text]
202. Freeman D, **Price D**, et al. Questions for COPD diagnostic screening in a primary care setting. *Respir Med* 2005; 99(10): 1311-8. [PubMed] [Full Text]
203. Ryan D, **Price D**, et al. Mobile phone technology in the management of asthma. *J Telemed Telecare* 2005; 11(Suppl 1): 43-6. [PubMed] [Full Text]
204. Pinnock H, **Price D**, et al. General practitioners with a special interest in respiratory medicine: national survey of UK primary care organisations. *BMC Health Serv Res* 2005; 5: 40. [PubMed] [Full Text]
205. Ruigomez A, **Price D**, et al. Gastroesophageal reflux disease and asthma: a longitudinal study in UK general practice. *Chest* 2005; 128(1): 85-93. [PubMed] [Full Text]
206. Thomas M, **Price D**, et al. The prevalence of dysfunctional breathing in adults in the community with and without asthma. *Prim Care Respir J* 2005; 14(2): 78-82. [PubMed] [Full Text]
207. **Price D**, et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. *Clin Exp Allergy* 2005; 35(3): 282-7. [PubMed] [Full Text]
208. Pinnock H, **Price D**, et al. Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. *Br J Gen Pract* 2005; 55(511): 119-24. [PubMed] [Full Text]
209. Thomas M, **Price D**, et al. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. *Pediatrics* 2005; 115(1): 129-34. [PubMed] [Full Text]
210. Barnes N, **Price D**, et al. The national montelukast survey. *J Allergy Clin Immunol* 2005; 115(1): 47-54. [PubMed] [Full Text]
211. **Price D**, et al. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. *Curr Med Res Opin* 2004; 20(10): 1671-9. [PubMed] [Full Text]
212. Ind PW, **Price D**, et al. Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study. *Respir Med* 2004; 98(5): 464-75. [PubMed] [Full Text]
213. Levy ML, **Price D**, et al. Inadequacies in UK primary care allergy services: national survey of current provisions and perceptions of need. *Clin Exp Allergy* 2004; 34(4): 518-9. [PubMed] [Full Text]
214. Pinnock H, **Price D**, et al. A pilot study to assess the feasibility and acceptability of undertaking acute asthma professional development in three different UK primary care settings. *Prim Care Respir J* 2003; 12: 7-11. [Full Text]

215. Pinnock H, **Price D**, et al. Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. *BMJ* 2003; 326(7387): 477-9. [PubMed] [Full Text]
216. **Price D**, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. *Thorax* 2003; 58(3): 211-6. [PubMed] [Full Text]
217. Thomas M, **Price D**, et al. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. *Thorax* 2003; 58(2): 110-5. [PubMed] [Full Text]
218. **Price DB**, et al. Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. *Respir Med* 2004; 98(1): 17-24. [PubMed] [Full Text]
219. **Price D**, et al. Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. *Respir Med* 2003; 97(1): 12-9. [PubMed] [Full Text]
220. Moffat M, **Price D**, et al. General practitioners' understanding of severe and difficult asthma: a qualitative study. *Prim Care Respir J* 2002; 11(3): 99-102. [Full Text]
221. **Price D**, et al. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. *Thorax* 2002; 57(9): 791-8. [PubMed] [Full Text]
222. **Price D**, et al. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. *Pharmacoeconomics* 2002; 20(10): 653-64. [PubMed] [Full Text]
223. Juniper EF, **Price DB**, et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. *Chest* 2002; 121(6): 1824-32. [PubMed] [Full Text]
224. **Price D**, et al. The burden of paediatric asthma is higher than health professionals think: results from the Asthma In Real Life (AIR) study. *Prim Care Respir J* 2002; 11(2): 30-3. [Full Text]
225. **Price DB**, Freeman D. The BREATH (Breathlessness Research, Expectations and Treatment hopes) study: findings of a pilot study in four countries. *Prim Care Respir J* 2002; 11(Suppl 1): s12-s14.
226. **Price DB**, et al. Use of Montelukast in tapering inhaled corticosteroid therapy: an open-label, 48-week trial. *Curr Ther Res* 2001; 62(11): 743-55. [Full Text]
227. **Price DB**, et al. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. *Respir Med* 2001; 95(1): 83-9. [PubMed] [Full Text]
228. **Price D**, et al. Asthma and analgesics: A patient awareness study. *Asthma J* 2000; 5: 191.
229. **Price D**, Wolfe S. Delivery of asthma care: patients' use of and views on healthcare services, as determined from a nationwide interview survey. *Asthma J* 2000; 5: 141-4.
230. **Price D**, et al. The AIR study: asthma in real life. *Asthma J* 1999; 4: 74-8.
231. **Price D**, et al. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. *Int J Clin Pract* 1999; 53(1): 31-6. [PubMed]
232. **Price D**, et al. Concerns and misconceptions regarding steroid therapy in asthma: findings and impact of a public meeting. *Asthma Gen Pract* 1998; 6(3): 43-4. [Full Text]
233. **Price DB**, et al. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. *Respir Med* 1998; 92(11): 1302-4. [PubMed] [Full Text]
234. **Price DB**, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. *Respir Med* 1998; 92(2): 351-3. [PubMed] [Full Text]
235. Gruffydd-Jones K, **Price DB**, et al. A within-patient comparison of subcutaneous and oral sumatriptan in the acute treatment of migraine in general practice. *Cephalalgia* 1997; 17(1): 31-6. [PubMed] [Full Text]

Guideline Participation: Final Publications

1. Brożek JL, **Price D**, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines - 2016 revision. *J Allergy Clin Immunol* 2017; 140(4): 950-958. [PubMed] [Full Text]
2. Sin DD, **Price D**, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. *Eur Respir J* 2016; 48(3): 664-73. [PubMed] [Full Text]
3. Bousquet J, **Price D**, et al.; MASK study group. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. *J Allergy Clin Immunol* 2016; 138(2): 367-74. [PubMed] [Full Text]
4. Bousquet J, **Price D**, et al. MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. *Allergy* 2015; 70(11): 1372-92. [PubMed] [Full Text]
5. Bousquet J, **Price D**, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). *Eur Respir J* 2014; 44(2): 304-32. [PubMed] [Full Text]
6. **Price D**, et al. A guide to performing quality assured diagnostic spirometry. *Education for Health* 2013. [Full Text]
7. **Price D**, et al. The primary care management of asthma in real-life settings. *Guidelines in practice* 2013; 49: 1-5. [Link]
8. Griffiths C, **Price D**, et al. Delivery/Organisation of Care. Brown K, Thompson L, Twaddle S (eds). *British guideline on the management of asthma: a national clinical guideline*. : British Thoracic Society and Scottish Intercollegiate Guidelines Network; 2012. pp. 94-7. [Full Text].
9. Bousquet J, **Price D**, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. *J Allergy Clin Immunol* 2012; 130(5): 1049-62. [PubMed] [Full Text]
10. WHO Collaborating Center for Asthma and Rhinitis, Bousquet J, **Price D**, et al. Severe chronic allergic (and related) diseases: a uniform approach – a MeDALL-GA²LEN-ARIA position paper. *Int Arch Allergy Immunol* 2012; 158(3): 216-31. [PubMed] [Full Text]
11. Fokkens WJ, **Price D**, et al. European position paper on rhinosinusitis and nasal polyps 2012. *Rhinology* 2012; 50(Suppl 23): 1-298. [PubMed] [Full Text]

12. Fokkens WJ, **Price D**, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinology* 2012; 50(1): 1-12. [PubMed]
13. Bousquet J, **Price D**, et al.; in collaboration with the WHO Collaborating Center of Asthma and Rhinitis (Montpellier). Development and implementation of guidelines in allergic rhinitis – an ARIA-GA²LEN paper. *Allergy* 2010; 65(10): 1212-21. [PubMed] [Full Text]
14. Brozek JL, et al.; Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol* 2010; 126(3): 466-76. [PubMed] [Full Text]
15. Pavord I, **Price D**. Utilising budesonide/formoterol in a single inhaler for relief and maintenance in asthma: BTS/SIGN recommendations. *Prescriber Suppl* 2010: 1-8.
16. Jones PW, et al. Development and first validation of the COPD Assessment Test. *Eur Respir J* 2009; 34(3): 648-54. [PubMed] [Full Text]
17. Bousquet J, et al.; Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. Unmet needs in severe chronic upper airway disease (SCUAD). *J Allergy Clin Immunol* 2009; 124(3): 428-33. [PubMed] [Full Text]
18. Thomas M, **Price D**, et al. EPOS Primary Care Guidelines: European position paper on the primary care diagnosis and management of rhinosinusitis and nasal polyps 2007: a summary. *Prim Care Respir J* 2008; 17(2): 79-89. [PubMed] [Full Text]
19. Griffiths C, **Price D**, et al. Delivery/Organisation of Care. Johnston SL, Mitchell DM (eds). *British guideline on the management of asthma: a national clinical guideline*. : British Thoracic Society and Scottish Intercollegiate Guidelines Network; 2008. pp. 94-7. [Full Text]. Published in *Thorax* 2008; 63(Suppl 4): iv1-121. [PubMed] [Full Text]
20. Bousquet J, **Price D**, et al.; World Health Organization; GA²LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen). *Allergy* 2008; 63(Suppl 86): 8-160. [PubMed] [Full Text]
21. Thomas M, **Price D**, et al. *Consensus guideline on the use of inhaler devices in asthma*, Guidelines Suppl 2007 ed. Buckinghamshire, England: Medendium Group Publishing Limited; 2007.
22. Fokkens W, et al.; European Position Paper on Rhinosinusitis and Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. *Rhinology* 2007; 45(Suppl 20): 1-139. [PubMed] [Full Text]
23. Passalacqua G, Durham SR; in cooperation with the Global Allergy and Asthma European Network (GA²LEN). Allergic rhinitis and its impact on asthma update: allergen immunotherapy. *J Allergy Clin Immunol* 2007; 119(4): 881-91. [PubMed] [Full Text]
24. Bousquet J, **Price D**, et al.; GA²LEN. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA²LEN). *Allergy* 2006; 61(9): 1086-96. [PubMed] [Full Text]
25. **Price D**, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. *Prim Care Respir J* 2006; 15(1): 58-70. [PubMed] [Full Text]
26. Levy ML, **Price DB**, et al. International Primary Care Respiratory Group (IPCRG) guidelines: diagnosis of respiratory diseases in primary care. *Prim Care Respir J* 2006; 15(1): 20-34. [PubMed] [Full Text]
27. Levy M, **Price D**, et al. Diagnosis. Grouse L, DeWeerd S (eds). *The International Primary Care Airways Group (IPAG). Diagnosis and management handbook. Chronic airways diseases: a guide for primary care physicians*. : MCR Vision Inc; 2005. pp. 1-13. [Full Text]
28. **Price DB**, Thomas MD; Asthma UK. Where next in clinical asthma research? An Asthma UK consultation on clinical asthma research strategy. *Asthma UK* 2004.
29. **Price D**; Members of the Workshops. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. *Allergy* 2004; 59(4): 373-87. [PubMed] [Full Text]
30. Bousquet J, **Price D**, et al.; European Academy of Allergy and Clinical Immunology (EAACI); Allergic Rhinitis and its Impact on Asthma (ARIA). Requirements for medications commonly used in the treatment of allergic rhinitis. *Allergy* 2003; 58: 192-7. [PubMed] [Full Text]
31. **Price D**; British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. *Thorax* 2003; 58(Suppl 1): i1-94. [PubMed] [Full Text]
32. Bousquet J, **Price D**, et al.; and the Workshop Expert Panel. Allergic Rhinitis and its Impact on Asthma (ARIA): in collaboration with the World Health Organization. *Allergy* 2002; 57(9): 841-55. [PubMed] [Full Text]
33. Scottish Intercollegiate Guidelines Network (SIGN). *Community management of lower respiratory tract infection in adults: a national clinical guideline*. Edinburgh; 2002.
34. **Price D**; for the British Thoracic Society Air Travel Guidelines Working Party. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Summary for primary care. *Thorax* 2002; 57(4):1-2. [PubMed] [Full Text]
35. Bousquet J, **Price D**, et al.; Aria Workshop Group; in collaboration with the World Health Organization. Allergic rhinitis and its impact on asthma. *108* 2001; 108(Suppl 5): S147-333. [PubMed] [Full Text]

Reviews and Discussion

1. Vandenplas O, **Price D**, et al. Impact of rhinitis on work productivity: a systematic review. *J Allergy Clin Immunol Pract* 2017.
2. Sonnappa S, **Price DB**, et al. Extrafine versus fine inhaled corticosteroids in relation to asthma control: a systematic review and meta-analysis of observational real-life studies. *J Allergy Clin Immunol Pract* 2017.
3. **Price D**, et al. Asthma referrals: a key component of asthma management that needs to be addressed. *J Asthma Allergy* 2017; 10: 209-223. [PubMed] [Full Text]
4. Costello RW, **Price D**, et al. Effective deployment of technology-supported management of chronic respiratory conditions: a call for stakeholder engagement. *Pragmat Obs Res* 2017; 8: 119-128. [PubMed] [Full Text]
5. **Price D**, et al. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 141-168. [PubMed] [Full Text]

6. Bousquet J, **Price D**, et al. Building bridges for innovation in ageing: synergies between action groups of the EIP on AHA. *J Nutr Health Aging* 2017; 21(1): 92–104. [PubMed] [Full Text]
7. Bousquet J, **Price D**, et al. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. *Clin Transl Allergy* 2016; 6: 47. [PubMed] [Full Text]
8. Vrijens B, **Price D**, et al. What we mean when we talk about adherence in respiratory medicine. *J Allergy Clin Immunol Pract* 2016; 4(5): 802-12. [PubMed] [Full Text]
9. Braido F, **Price D**, et al.; on behalf of the Respiratory Effectiveness Group. “Trying, but failing” — the role of inhaler technique and mode of delivery in respiratory medication adherence. *J Allergy Clin Immunol Pract* 2016; 4(5): 823-32. [PubMed] [Full Text]
10. Bousquet J, **Price D**, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). *Clin Transl Allergy* 2016; 6: 29. [PubMed] [Full Text]
11. Djukanovic R, **Price D**, et al. IgE-mediated asthma: new revelations and future insights. *Respir Med* 2016; 112: 128-9. [PubMed] [Full Text]
12. Klimek L, **Price D**, et al. Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. *Expert Rev Clin Pharmacol* 2016; 9(5): 705-14. [PubMed] [Full Text]
13. Lenney W, **Price D**, et al. Lessons learnt from a primary care asthma improvement project. *NPJ Prim Care Respir Med* 2016; 26: 15075. [PubMed] [Full Text]
14. D'Urzo T, **Price D**, et al. Dual bronchodilator therapy with acclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. *Expert Rev Respir Med* 2015; 9(5): 519-32. [PubMed] [Full Text]
15. **Price D**, et al. Current controversies and challenges in allergic rhinitis management. *Expert Rev Clin Immunol* 2015; 11(11): 1205-17. [PubMed] [Full Text]
16. D'Urzo A, **Price D**, et al. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. *Expert Opin Pharmacother* 2015; 16(12): 1845-60. [PubMed] [Full Text]
17. Brand PL, **Price D**, et al.; ERS Task Force Monitoring Asthma in Children. Monitoring asthma in childhood: symptoms, exacerbations and quality of life. *Eur Respir Rev* 2015; 24(136): 187-93. [PubMed] [Full Text]
18. Pijnenburg MW, **Price D**, et al. Monitoring asthma in children. *Eur Respir J* 2015; 45(4): 906-25. [PubMed] [Full Text]
19. Bousquet J, **Price D**, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. *Expert Opin Pharmacother* 2015; 16(6): 913-28. [PubMed] [Full Text]
20. **Price D**, et al. Real-world research and its importance in respiratory medicine. *Breathe (Sheff)* 2015; 11(1): 26-38. [PubMed] [Full Text]
21. van Aalderen WM, **Price D**, et al. How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. *NPJ Prim Care Respir Med* 2015; 8(25): 14088. [PubMed] [Full Text]
22. Bousquet J, **Price D**, et al. Dymista®: in a class of its own for the treatment of allergic rhinitis. *Key Opinions in Medicine* 2015. [Full Text]
23. **Price D**. Expert Review: The significance of inhaler technique and how to improve it. *ONdrugDelivery* 2014; 53: 4-7. [Full Text]
24. Bousquet J, **Price D**, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. *Curr Pharm Des* 2014; 20(38): 5928-44. [PubMed] [Full Text]
25. Zibrak JD, **Price D**. Interstitial lung disease: raising the index of suspicion in primary care. *NPJ Prim Care Respir Med* 2014; 24: 14054. [PubMed] [Full Text]
26. **Price D**, et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? *NPJ Prim Care Respir Med* 2014; 24: 14023. [PubMed] [Full Text]
27. **Price D**, Hillyer EV. Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. *Expert Rev Respir Med* 2014; 8(3): 275-91. [PubMed] [Full Text]
28. Bjermer L, **Price D**, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. *Respir Med* 2014; 108(6): 830-41. [PubMed] [Full Text]
29. **Price D**, et al. Integrating evidence for managing asthma in patients who smoke. *Allergy Asthma Immunol Res* 2014; 6(2): 114–20. [PubMed] [Full Text]
30. Roche N, **Price D**, et al. Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. *Ann Am Thorac Soc* 2014; 11(Suppl 2): S99-104. [PubMed] [Full Text]
31. **Price D**, et al. Complementing the randomized controlled trial evidence base. Evolution not revolution. *Ann Am Thorac Soc* 2014; 11(Suppl 2): S92-8. [PubMed] [Full Text]
32. Martin R, **Price D**, et al. The arch conference declaration. Helping to further the science of pragmatic research. *Ann Am Thorac Soc* 2014; 11(Suppl 2): S83-4. [PubMed] [Full Text]
33. Bousquet J, **Price D**, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing: from concept to implementation and policies. *Curr Pharm Des* 2014; 20(38): 5928-44. [PubMed] [Full Text]
34. Dekhuijzen PNR, **Price D**, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. *Respir Med* 2013; 107(12): 1817-21. [PubMed] [Full Text]
35. Roche N, **Price D**, et al.; Respiratory Effectiveness Group. Integrating real-life studies in the global therapeutic research framework. *Lancet Respir Med* 2013; 1(10): e29-30. [PubMed] [Full Text]
36. **Price D**, Brusselle G. Challenges of COPD diagnosis. *Expert Opin Med Diagn* 2013 Nov; 7(6): 543-56. [PubMed] [Full Text]
37. Roche N, **Price D**, et al. Effectiveness of inhaler devices in adult asthma and COPD. *Euro Med J* 2013; 1: 64-71. [Full Text]
38. **Price D**, et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. *Prim Care Respir J* 2013; 22(1): 92-100. [PubMed] [Full Text]
39. **Price D**, et al. Efficacy versus effectiveness trials: informing guidelines for asthma management. *Curr Opin Allergy Clin Immunol* 2013; 13(1): 50-7. [PubMed] [Full Text]
40. Bonini M, **Price D**, et al. What we should learn from the London Olympics. *Curr Opin Allergy Clin Immunol* 2013; 13(1): 1-3. [PubMed] [Full Text]

41. Inhaler Error Steering Committee, **Price D**, Bousquet J, et al. Inhaler competence in asthma: common errors, barriers to use and recommended solutions. *Respir Med* 2013; 107(1): 37-46. [PubMed] [Full Text]
42. **Price D**, et al. Real-life asthma strategies: the missing piece in the jigsaw. *Treatment Strategies - Respiratory* 2013; 3(2): 37-46.
43. **Price D**, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting $\beta(2)$ -agonist combinations in the treatment of asthma. *Respir Med* 2012; 106(Suppl 1): S4-8. [PubMed] [Full Text]
44. **Price D**, et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. *Curr Allergy Asthma Rep* 2011; 11(6): 526-38. [PubMed] [Full Text]
45. Decramer M, **Price D**, et al. New horizons in early stage COPD: improving knowledge, detection and treatment. *Respir Med* 2011; 105(11): 1576-87. [PubMed] [Full Text]
46. Sims EJ, **Price D**, et al. Current control and future risk in asthma management. *Allergy Asthma Immunol Res* 2011; 3(4): 217-25. [PubMed] [Full Text]
47. **Price D**, et al. Differences between asthma and COPD: how to make the diagnosis in primary care. *Hot Topics in Respiratory Medicine* 2011; 16: 7-14.
48. Jones R, **Price D**, et al. Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2011; 6: 289-96. [PubMed] [Full Text]
49. **Price D**, et al. Earlier diagnosis and earlier treatment of COPD in primary care. *Prim Care Respir J* 2011; 20(1): 15-22. [PubMed] [Full Text]
50. **Price DB**, et al. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. *Mayo Clin Proc* 2010; 85(12): 1122-9. [PubMed] [Full Text]
51. **Price D**, et al. The use of roflumilast in COPD: a primary care perspective. *Prim Care Respir J* 2010; 19(4): 342-51. [PubMed] [Full Text]
52. Haughney J, **Price D**, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. *Respir Med* 2010; 104(9): 1237-45. [PubMed] [Full Text]
53. **Price D**. Asthma and allergic rhinitis: linked in treatment and outcomes. *Ann Thorac Med* 2010; 5(2): 63-4. [PubMed] [Full Text]
54. Pinnock H, **Price D**, et al. Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care. *Prim Care Respir J* 2010; 19(1): 75-83. [PubMed] [Full Text]
55. **Price D**. Spirometry and questionnaire use for early diagnosis of chronic obstructive pulmonary disease. *Hot Topics in Respiratory Medicine* 2010; 5: 13-8.
56. **Price D**, Siddall R. COPD management: new and existing therapy options. *Future Prescriber* 2010; 11(1): 12-6. [Full Text]
57. Costa DJ, **Price D**, et al. Guidelines for allergic rhinitis need to be used in primary care. *Prim Care Respir J* 2009; 18(4): 250-7. [PubMed] [Full Text]
58. Chrystyn H, **Price D**. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. *Prim Care Respir J* 2009; 18(4): 243-9. [PubMed] [Full Text]
59. Hodder R, **Price D**. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. *Int J Chron Obstruct Pulmon Dis* 2009; 4: 381-90. [PubMed] [Full Text]
60. Soriano JB, **Price D**, et al. Screening for and early detection of chronic obstructive pulmonary disease. *The Lancet* 2009; 374(9691): 721-32. [PubMed] [Full Text]
61. **Price D**, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. *Prim Care Respir J* 2009; 18(3): 216-23. [PubMed] [Full Text]
62. Chrystyn H, **Price D**. What you need to know about inhalers and how to use them. *Prescriber* 2009; 20(12): 4-52. [Full Text]
63. **Price D**, et al. Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. *Expert Opin Drug Metab Toxicol* 2009; 5(4): 417-24. [PubMed] [Full Text]
64. Holgate S, **Price D**, et al. The Brussels Declaration: the need for change in asthma management. *Eur Respir J* 2008; 32(6): 1433-42. [PubMed] [Full Text]
65. Haughney J, **Price D**, et al. Achieving asthma control in practice: understanding the reasons for poor control. *Respir Med* 2008; 102(12): 1681-93. [PubMed] [Full Text]
66. Thomas M, **Price D**. Impact of comorbidities on asthma. *Expert Rev Clin Immunol* 2008; 4(6): 731-42. [PubMed] [Full Text]
67. Bush A, **Price D**. Pro-con debate: Inhaled corticosteroids should not be prescribed in primary care to children under two years of age - the case for. *Prim Care Respir J* 2008; 17(3): 176-80. [PubMed] [Full Text]
68. **Price D**. The use of omalizumab in asthma. *Prim Care Respir J* 2008; 17(2): 62-72. [PubMed] [Full Text]
69. Cruz AA, **Price D**, et al.; ARIA Initiative Scientific Committee. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA²LEN. *Allergy* 2007; 62(Suppl 84): 1-41. [PubMed] [Full Text]
70. Horne R, **Price D**, et al. Can asthma control be improved by understanding the patient's perspective?. *BMC Pulm Med* 2007; 7: 8. [PubMed] [Full Text]
71. **Price D**, Holgate ST. Improving outcomes for asthma patients with allergic rhinitis: conclusions from the MetaForum conferences. *BMC Pulm Med* 2006; 6(Suppl 1): S7. [PubMed] [Full Text]
72. **Price D**, Thomas M. Breaking new ground: challenging existing asthma guidelines. *BMC Pulm Med* 2006; 6(Suppl 1): S6. [PubMed] [Full Text]
73. Holgate ST, **Price D**, et al. Asthma out of control? A structured review of recent patient surveys. *BMC Pulm Med* 2006; 6(Suppl 1): S2. [PubMed] [Full Text]
74. **Price D**. The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease. *Expert Rev Pharmacoecon Outcomes Res* 2006; 6(4): 391-405. [PubMed] [Full Text]
75. **Price D**. Impact of antibiotic restrictions: the physician's perspective. *Clin Microbiol Infect* 2006; 12(Suppl 5): 3-9. [PubMed] [Full Text]
76. Freeman D, **Price D**. ABC of chronic obstructive pulmonary disease. Primary care and palliative care. *BMJ* 2006; 333(7560): 188-90. [PubMed] [Full Text]

77. Passalacqua G, **Price D**, et al. ARIA update: I—Systematic review of complementary and alternative medicine for rhinitis and asthma. *J Allergy Clin Immunol* 2006; 117(5): 1054-62. [PubMed] [Full Text]
78. **Price D**. The way forward: dry powder inhalers should only be switched with physician agreement and patient training. *Int J Clin Pract* 2005; 59(Suppl 149): 36-7. [PubMed] [Full Text]
79. **Price D**. Do healthcare professionals think that dry powder inhalers can be used interchangeably? *Int J Clin Pract Suppl* 2005; (149): 26-9. [PubMed] [Full Text]
80. **Price D**, et al. Could interchangeable use of dry powder inhalers affect patients? *Int J Clin Pract Suppl* 2005; (149): 3-6. [PubMed] [Full Text]
81. **Price D**, et al. Progressive breathlessness in COPD - The role of hyperinflation and its pharmacological management. *Prim Care Respir J* 2005; 14(6): 285-93. [PubMed] [Full Text]
82. **Price D**, Cross S. Clinical management. Getting up to scratch. *Health Serv J* 2005; 115(5962): 30-2. [PubMed]
83. Buhl R, **Price D**. Patients' perceptions of well-being using a guided self-management plan in asthma. *Int J Clin Pract* 2004; 58(Suppl 141): 26-32. [Full Text]
84. Reid J, **Price D**, et al. Development of a primary-care tool to assess treatment success in COPD: consensus report from a closed meeting of respiratory and primary-care specialists. *Prim Care Respir J* 2004; 13(2): 99-104. [PubMed] [Full Text]
85. **Price D**. Measuring the effectiveness of asthma therapy. *European Respiratory Review* 2004; 13: 98-101.
86. **Price D**, et al. The importance of preserving choice in inhalation therapy: the CFC transition and beyond. *Journal of Drug Assessment* 2004; 7: 45-61.
87. Burney P, **Price D**, et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. *Eur Respir J Suppl* 2003; 43: 1s-44s. [PubMed] [Full Text]
88. **Price D**. Chronic obstructive pulmonary disease – issues in primary care. *N Z Fam Physician* 2003; 30(3): 162-4.
89. Thomas M, **Price D**, et al. Database studies in asthma pharmacoeconomics: uses, limitations and quality markers. *Expert Opin Pharmacother* 2003; 4(3): 351-8. [PubMed] [Full Text]
90. Cleland J, **Price D**, et al. Pharmacoeconomics of asthma treatment. *Expert Opin Pharmacother* 2003; 4(3): 311-8. [PubMed] [Full Text]
91. Williams S, **Price D**, et al. General practitioners with a special clinical interest: a model for improving respiratory disease management. *Br J Gen Pract* 2002; 52(483): 838-43. [PubMed]
92. Duerden M, **Price D**. Inhalers: education and training needs. *Curr Ther (Seaforth)* 2002; 43(5): 21-6, 28-9.
93. Duerden M, **Price D**. Training issues in inhaler use. *N Ethics J* 2001; 4(11): 31-42.
94. Freeman D, **Price D**. Implications of health economics for prescribers. *Respiratory Care Matters* 2001; 6(2): 12-3.
95. Duerden M, **Price D**. Training Issues in the use of inhalers. *Disease Management and Health Outcomes* 2001; 9(2): 75-87. [Full Text]
96. **Price D**. Choices at step 3: increase corticosteroid, add in beta- agonist or add in leukotriene receptor antagonist?. *RSM Suppl* 2000.
97. **Price D**. Tolerability of montelukast. *Drugs* 2000; 59(Suppl 1): 35-42. [PubMed] [Full Text]
98. **Price D**. Limitations of anti-inflammatory asthma treatments - Concerns of asthma nurses. *Prescriber Suppl* 1998.
99. **Price D**. GPs' frustrations. *Prescriber Suppl* 1998.
100. **Price D**. GPs get new choice in management strategy. *RX Magazine* 1998; 1(1): 15.
101. **Price D**. COPD takes its toll. *Chemist & Druggist (The Newsweek for Pharmacy)* 1997.
102. **Price D**. What are the cost implications of intensive primary care asthma management? *Re:fund (Magazine of the West Midlands Association Fundholding Practices)* 1997; 14: 19.
103. Gray P, **Price D**, et al. Occupational asthma in a new employee. *Practitioner* 1996; 240(1568): 619-22, 625.
104. **Price D**. Patient attitudes to asthma medications. *Respiratory Disease in Practice* 1995; 12(4): 13-6.
105. **Price D**. Steroid phobia. *Respiratory Disease in Practice* 1994; 11(3): 10-3.

Editorials

1. Hillyer EV, **Price DB**, et al; on behalf of the Respiratory Effectiveness Group, Small Airways Study Group. Harmonizing the nomenclature for therapeutic aerosol particle size. *J Aerosol Med Pulm Drug Deliv* 2017; 31: 1-3.
2. van Boven JFM, **Price DB**, et al. Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. *Eur Respir J* 2017; 49(5): 1700076. [PubMed] [Full Text]
3. Bardin PG, **Price D**, et al. Managing asthma in the era of biological therapies. *Lancet Respir Med* 2017; 5(5): 376-8. [PubMed] [Full Text]
4. Winchester CC, **Price D**, et al. A practical tool for primary care antimicrobial stewardship in children. *Lancet Respir Med* 2016; 4(11): 850-2. [PubMed] [Full Text]
5. Van Ganse E, **Price D**. Respiratory medication adherence: toward a common language and a shared vision. *J Allergy Clin Immunol Pract* 2016; 4(5): 799-801. [PubMed] [Full Text]
6. **Price DB**. Time to get real: critical and imperative change required in evidence evaluation. *J Thorac Dis* 2016; 8(Suppl 5): S431-4. [PubMed] [Full Text]
7. **Price D**. Letter from the editor. *European Respiratory and Pulmonary Diseases* 2015; 1(1): 13. [Full Text]
8. Steenbruggen I, **Price D**, et al. A BOLD statement on how to case-find moderate/severe COPD. *Eur Respir J* 2013; 41: 503-4. [PubMed] [Full Text]
9. Sims EJ, **Price D**. Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD. *Prim Care Respir J* 2012; 21(2): 128-30. [PubMed] [Full Text]
10. Lenney W, **Price D**, et al. Clinical trials and tribulations: the MASCOT study. *Thorax* 2011; 66(6): 457-8. [PubMed] [Full Text]
11. Papi A, **Price D**, et al. Inhaler devices for asthma: a call for action in a neglected field. *Eur Respir J* 2011; 37(5): 982-5. [PubMed] [Full Text]

12. Haughney J, **Price D**, et al. Improving clinician-patient communication in asthma: the HARP project. *Allergy* 2010; 65(4): 413-4. [PubMed] [Full Text]
13. Haughney J, **Price D**, et al. Driving asthma care in Europe: the Brussels Declaration. *Prim Care Respir J* 2009; 18(2): 55-6. [PubMed] [Full Text]
14. Crockett A, **Price D**. Co-morbid disease in COPD – more than a coincidence. *Int J Chron Obstruct Pulmon Dis* 2007; 2(4): 399-400. [PubMed]
15. Levy ML, **Price D**, et al.; UK General Practice Airways Group (GPIAG). The UK General Practice Airways Group (GPIAG): its formation, development, and influence on the management of asthma and other respiratory diseases over the last twenty years. *Prim Care Respir J* 2007; 16(3): 132-9. [PubMed] [Full Text]
16. **Price D**. Editorial: - Allergic rhinitis and asthma. *Drugs in Context* 2006; 2(10): 415.
17. **Price D**. Foreword: Can dry powder inhalers be used interchangeably?. *Int J Clin Pract* 2005; 59(Suppl 149): 1. [Full Text]
18. Cleland J, **Price D**. Achieving optimal asthma control: can this be informed by recent studies of professional-patient communication?. *Prim Care Respir J* 2005; 14(5): 233-5. [PubMed] [Full Text]
19. Ryan D, **Price D**. Editorial – Allergic rhinitis. *Drugs in Context* 2005; 1(11): 579.
20. **Price D**, Duerden M. Chronic obstructive pulmonary disease: the lack of a national service framework should not allow us to ignore it. *BMJ* 2003; 326(7398): 1046-7. [PubMed] [Full Text]
21. **Price DB**. Foreword. *Clin Drug Investig* 2002; 22(Suppl 2).
22. **Price D**. Health care utilisation for respiratory symptoms. *Prim Care Respir J* 2001; 10(3): 56-7.
23. **Price D**. The next three years. *Asthma in Gen Prac* 1999; 7(2): 25.
24. Ryan D, **Price D**, et al. New GPIAG chair in primary care respiratory medicine to be hosted at Aberdeen. *Asthma in Gen Prac* 1999; 7(1): 2.

Books and Book Chapters

1. Thomas M, **Price D**, et al. *A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults*, 21 ed. Winchester: NIHR Journals Library; 2017.
2. Soriano JB, **Price D**. Screening and case finding. Anzueto A, Heijdra Y, Hurst JR (eds). *Controversies in COPD*, 69 ed. : ERS Monograph; 2015. pp. 1-25. [Full Text]
3. Gruffydd-Jones K, **Price D**, et al. *The 10-minute consultation: chronic obstructive pulmonary disease*. London, UK: Cedilla Publishing Ltd; 2008. [Full Text]
4. Freeman D, **Price D**. Primary care. Stockley R, Rennard S, Rabe K, Celli B (eds). *Chronic obstructive pulmonary disease*. Massachusetts: Blackwell Publishing; 2007. pp. 579-84. [Full Text]
5. Freeman D, **Price D**. Primary care and palliative care. Currie GP (ed). *ABC of COPD*. Oxford, UK: Blackwell Publishing; 2007. pp. 31–3. [Full Text]
6. **Price D**. The one-airway concept. Haughney J (ed). A primary care guide to allergy. Dartford: Magister Consulting; 2006.
7. Bull E, **Price D**. A simple guide to asthma. Bull E, **Price D** (eds). Long Hanborough: CSF Medical Communications; 2005. [Full Text]
8. Thomas M, **Price D**. Asthma drug treatment patient notes. Kassianos G, Chung F, Gruffydd-Jones K, Thomas M, **Price D** (eds). *Best medicine: asthma*. Long Hanborough: CSF Medical Communications; 2005. pp. 297-302.
9. Thomas M, **Price D**. Asthma patient notes. Kassianos G, Chung F, Gruffydd-Jones K, Thomas M, **Price D** (eds). *Best medicine: asthma*. Long Hanborough: CSF Medical Communications; 2005. pp. 21-4.
10. **Price D**, et al. Churchill's in clinical practice series: COPD and asthma. Edinburgh: Churchill Livingstone; 2004.
11. Thomas M, **Price D**. The diagnosis and assessment of asthma in primary care. O'Connor B, Scadding G (eds). *Key advances in the clinical management of asthma 2*. London: Royal Society of Medicine Press; 2004. pp. 23-9.
12. Cleland J, **Price D**, et al. Use of nebulizers in primary care: issues and challenges. Boe J, O'Driscoll BR, Dennis JH (eds). *Practical handbook of nebulizer therapy*. London: Martin Dunitz; 2004. pp. 211-32. [Full Text]
13. **Price D**. What are the issues in delivering care in primary care?. Johnston SL, Holgate ST (eds). *Asthma: critical debates*. Oxford: Blackwell Science; 2002. pp. 319-42. [Full Text]

Reports

1. Donner CF, **Price D**, et al. Inhalation therapy in the next decade: determinants of adherence to treatment in asthma and COPD. *Monaldi Arch Chest Dis* 2018; 88(886): 14-36. [Full Text]
2. Bousquet J, **Price D**, et al. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRIL report. *Clin Transl Allergy* 2017; 7: 37. [PubMed] [Full Text]
3. Chisholm A, **Price DB**, et al. 2016 Respiratory Effectiveness Group annual summit report — impact & influence of real-world respiratory evidence. *J Thorac Dis* 2016; 8(Suppl 5): S435-S444. [PubMed] [Full Text]
4. Muraro A, **Price D**, et al. European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015). *Allergy* 2015; 71(5): 583-7. [PubMed] [Full Text]
5. Muraro A, **Price D**, et al. European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015). *Rhinology* 2015; 53(4): 303-7. [PubMed] [Full Text]
6. **Price D**, van der Molen T. The Aberdeen primary care COPD research needs statement March 2001. *Prim Care Respir J* 2001; 10(2): 47-9.
7. Thoonen BPA, **Price D**, et al. Present and future management of asthma and COPD: proceedings from WONCA 1998. *Fam Pract* 1999; 16(3): 313-5. [PubMed] [Full Text]

Letters

1. Kerkhof M, **Price DB**. Reply [The effect of smoking on exacerbation risk in eosinophilic patients with chronic obstructive pulmonary disease]. *Eur Respir J* 2017; 50: 1702086. [PubMed] [Full Text]

2. Kerkhof M, **Price DB**, et al. Blood eosinophil count and exacerbation risk in patients with COPD. *Eur Respir J* 2017; 50(1): 1700761. [PubMed] [Full Text]
3. Guilbert TW, **Price DB**. Reply [Impact of spacers on therapeutic ratio with inhaled corticosteroids]. *J Allergy Clin Immunol Pract* 2017; 5(4): 1163-4. [Full Text]
4. Grigg J, **Price DB**, et al. Urinary prostanoids in preschool wheeze. *Eur Respir J* 2017; 49(2): 1601390. [PubMed] [Full Text]
5. Lipworth B, **Price DB**, et al. It is important to distinguish between HFrEF and HFpEF when interpreting these data. *Heart* 2016; 102(23): 1934. [PubMed] [Full Text]
6. **Price DB**, et al. Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up. *Multidiscip Respir Med* 2016; 11: 39. [Full Text]
7. van Boven JFM, **Price DB**, et al. COPD case finding: effective, but also cost-effective?. *Lancet Respir Med* 2016; 4(10): e49. [PubMed] [Full Text]
8. **Price DB**, et al. Inhaled corticosteroid dose-response on blood eosinophils in asthma – Authors' reply. *Lancet Respir Med* 2016; 4(1): e1-2. [PubMed] [Full Text]
9. Van Aalderen WMC, **Price DB**, et al. Reply [Inhaled corticosteroids for asthma therapy in young children: does aerosol particle size matter?]. *J Allergy Clin Immunol Pract* 2016; 4(2): 372-3. [Full Text]
10. **Price D**, Chrystyn H. Concept review of dry powder inhalers: correct interpretation of published data. *Multidiscip Respir Med* 2015; 10:36. [PubMed] [Full Text]
11. Roche N, **Price DB**, et al. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. *Am J Respir Crit Care Med* 2015; 191(8): 960-4. [PubMed] [Full Text]
12. **Price D**, et al. Feasibility and ethics. *Am J Respir Crit Care Med* 2013; 188(11): 1368-9. [PubMed] [Full Text]
13. Jones R, **Price D**, et al. GOLD COPD categories are not fit for purpose in primary care. *Lancet Respir Med* 2013; 1(1): e17. [PubMed] [Full Text]
14. **Price D**, et al. The authors reply [Leukotriene antagonists in asthma]. *N Engl J Med* 2011; 365(3): 273-4. [Full Text]
15. Jones RC, **Price DB**, et al. Implementing the change in National Institute for Health and Clinical Excellence guidance on airflow obstruction grading in chronic obstructive pulmonary disease. *Thorax* 2011; 66: 543-4. [Full Text]
16. Winchester CC, **Price D**, et al. Flawed comparative groups lead to flawed conclusions: response. *Chest* 2009; 136(4): 1185-6. [Full Text]
17. Thomas M, **Price D**. High-dose inhaled corticosteroid versus long-acting beta-agonist addition in asthma. *Chest* 2009; 135(5): 1404–5. [PubMed] [Full Text]
18. Cleland JA, **Price DB**. Implementing self-management plans for asthma patients. *Prescriber* 2004; 15: 76-9.
19. **Price DB**, et al. Letter to the editor [Association between antibiotic prescribing trends in general practice and community-acquired pneumonia mortality]. *Respir Med* 2004; 98(8): 801-3. [Full Text]
20. Thomas M, **Price D**. Asthma natural history and diagnosis. *Ann Fam Med* 2004. [Full Text]
21. **Price D**. My job as a respiratory professional. *The Airways Journal* 2003; 1.
22. Thomas M, **Price D**. Prenatal antibiotic exposure and subsequent atopy. *Am J Resp Crit Care Med* 2003; 167(11): 1578-9. [Full Text]
23. Pinnock H, **Price D**, et al. Authors' reply [Routine telephone review of asthma: further investigation is required]. *BMJ* 2003; 326(7401): 1267-8. [Full Text]
24. Thomas M, **Price D**. Chronic cough. Article is not consistent with WHO initiative on rhinitis and asthma. *BMJ* 2003; 326(7397): 1036. [PubMed] [Full Text]
25. Thomas M, **Price D**. Consistent rhinitis advice needed. *BMJ* 2003; 326(7383): 261. [Full Text]
26. Thomas M, **Price D**, et al. Cost effectiveness of asthma management strategies. *Pharmacoeconomics* 2002; 20(11): 789. [PubMed] [Full Text]
27. **Price D**. Pragmatic randomised controlled trials. *Prim Care Respir J* 2002; 11(2): 78. [Full Text]
28. Partridge M, **Price D**, et al. Guided self management plans for asthma. Advice should be simple and patient focused. *BMJ* 2001; 322(7294): 1121-2. [PubMed] [Full Text]